Compare GERN & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | TRTX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | 258 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 808.3M | 659.4M |
| IPO Year | N/A | N/A |
| Metric | GERN | TRTX |
|---|---|---|
| Price | $1.50 | $8.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.17 | ★ $9.83 |
| AVG Volume (30 Days) | ★ 14.8M | 720.7K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.55% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | $8.78 |
| Revenue Next Year | $43.75 | $4.14 |
| P/E Ratio | ★ N/A | $14.82 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $7.57 |
| 52 Week High | $2.01 | $9.85 |
| Indicator | GERN | TRTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 52.36 |
| Support Level | $1.44 | $8.48 |
| Resistance Level | $1.72 | $8.72 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 68.06 | 57.14 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.